# Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma

> **NCT03470805** · PHASE2 · COMPLETED · sponsor: **Grupo Español de Investigación en Cáncer de Ovario** · enrollment: 9 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT03470805
- **Lead sponsor:** Grupo Español de Investigación en Cáncer de Ovario
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-21
- **Primary completion:** 2022-07-27
- **Final completion:** 2022-07-27
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2022-09-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03470805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03470805, "Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03470805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*